In summary, we first demonstrated that the administration of AVE0991 activating Mas receptor improved neurological deficits, promoted hematoma absorption, reduced brain swelling, alleviated neuroinflammation, and neuronal apoptosis, partially through the Akt/Nrf2 signaling pathway following ICH (Fig. 9). This evidence concerns the gene AKT1 and hematoma.